Pacritinib

Pacritinib
Clinical data
Other names	SB1518
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene;
CAS Number	937272-79-2;
PubChem CID	46216796;
ChemSpider	28518965;
UNII	G22N65IL3O;
KEGG	D11768;
ChEMBL	ChEMBL2035187;
Chemical and physical data
Formula	C28H32N4O3
Molar mass	472.589 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5;
	InChI InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+; Key:HWXVIOGONBBTBY-ONEGZZNKSA-N;

Pacritinib (INN[1]) is a macrocyclic Janus kinase inhibitor that is being developed for the treatment of myelofibrosis. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3). The drug was in Phase III clinical trials as of 2013.[2]

The drug was given fast-track status in 2014.[3] In 2016, the FDA placed a full clinical hold on pacritinib due to concerns about increased mortality in patients receiving the drug in the "PERSIST-2" trial.[4] The clinical hold was lifted in January 2017.[5]

References

"International Nonproprietary Names for Pharmaceutical Substances (INN) List 104" (PDF). WHO Drug Information. 24 (4): 386. 2010.
"JAK-Inhibitoren: Neue Wirkstoffe für viele Indikationen". Pharmazeutische Zeitung (in German) (21). 2013.
Adams B (29 August 2016). "Struggling CTI reveals new pacritinib data, misses a primary endpoint". Fierce Biotech.
"CTI BioPharma's (CTIC) Pacritinib Placed on Full Clinical Hold; NDA Withdrawn". StreetInsider. 10 February 2016.
"CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib". PR Newswire. Retrieved 18 April 2017.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "International Nonproprietary Names for Pharmaceutical Substances (INN) List 104" (PDF). WHO Drug Information. 24 (4): 386. 2010.

[2] "JAK-Inhibitoren: Neue Wirkstoffe für viele Indikationen". Pharmazeutische Zeitung (in German) (21). 2013.

[3] Adams B (29 August 2016). "Struggling CTI reveals new pacritinib data, misses a primary endpoint". Fierce Biotech.

[4] "CTI BioPharma's (CTIC) Pacritinib Placed on Full Clinical Hold; NDA Withdrawn". StreetInsider. 10 February 2016.

[Newswire2017-5] "CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib". PR Newswire. Retrieved 18 April 2017.